Quinone Oxidoreductase 2 (NQO2) human

MFCD03458332

NA.54

Quinone oxidoreductase 2 has been used in a study to investigate whether recent advances in limiting paraquat′s toxicity makes it safer for use as an herbicide. Quinone oxidoreductase 2 has also been used in a study to investigate the NQO2-mediated toxicity of the chemotherapeutic drug CB1954.
The product from Sigma has been used to identify novel inhibitors of the enzyme NQO2. It has also been used to investigate the effect of afobazole on quinone reductase 2 activity.

Modulation of NQO2 activity can have effects on the levels and functions of the tumour suppressor, p53. Deletion of NQO2 can alter intra-cellular signalling via the NF-κB pathway.
Unique human oxidoreductase that uses Dihydronicotinamide riboside (NRH) as a cosubstrate, not NAD(P)H. Activates anticancer prodrugs. Putative melatonin receptor.

One unit will catalyze the oxidation of one micromole of 1-methyl-1,4-dihydronicotinamide to 1-methylnicotinamide per minute in the presence of menadione at pH 7.4 at 37 ℃.

contains 10% PBS buffer salts

200

expressed in E. coli

≥90% (SDS-PAGE)

lyophilized powder (one vial contains one mg protein)

≥100 units/mg protein

P16083

−20℃

human ... NQO2(4835)

13 - Non Combustible Solids

WGK 3

Eyeshields, Gloves, type N95 (US)